366 results on '"Krijgsman, Oscar"'
Search Results
2. Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
3. B cells and tertiary lymphoid structures promote immunotherapy response
4. Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
5. Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.
6. Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
7. Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.
8. Non-clinical evaluation of NT-175, an autologous T cell product engineered to express an HLA-A*02:01-restricted TCR targeting TP53 R175H and resistant to TGF-b inhibition.
9. MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance
10. FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice
11. Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
12. Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
13. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
14. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
15. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
16. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
17. Supplementary Fig. S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
18. Supplementary Table S5 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
19. Data from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
20. Supplementary Figure S1 from Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
21. FIGURE 2 from Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
22. Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
23. FIGURE 5 from Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
24. FIGURE 1 from Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
25. FIGURE 4 from Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
26. Data from Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
27. FIGURE 3 from Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
28. A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
29. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
30. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
31. Mammaprint® Translating Research into a Diagnostic Test
32. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
33. Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients
34. BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
35. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
36. Supplementary Table from Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges
37. Data from Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges
38. Supplementary Figure from Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges
39. Supplementary Data from Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
40. Supplementary Figures from Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
41. Data from Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
42. Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms
43. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases
44. An adverse tumor-protective effect of IDO1 inhibition
45. MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance
46. Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition
47. Focal chromosomal copy number aberrations in cancer—Needles in a genome haystack
48. Integrative epigenetic taxonomy of primary prostate cancer
49. XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
50. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.